Evidence map›Paper›PMID 41248180›Full record

ReviewThe Biochemical journal2025

The impact of RAS on cell differentiation in health and disease.

Carla Jane Duval, Sara Bottone, Elisabeth Schaffner-Reckinger, Daniel Kwaku Abankwa

Abstract readReview
In one paragraph

Review in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carla Jane Duval *Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, 4362, Luxembourg.ORCID 0000-0003-2254-3738
Sara Bottone *Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, 4362, Luxembourg.ORCID 0000-0002-4049-2332
Elisabeth Schaffner-Reckinger *Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, 4362, Luxembourg.ORCID 0000-0002-0321-3621
Daniel Kwaku AbankwaCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, 4362, Luxembourg.ORCID 0000-0003-2769-0745

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS proteins have been studied for more than 40 years, mainly in the context of cancer. Given that RAS signaling promotes cell cycle progression, it is commonly assumed that its main function is to drive cell proliferation. In this review, we will, however, address the roles of RAS during cell differentiation, which is intertwined with cell division during organismal development and tissue homeostasis in the adult. Our analysis suggests a far-reaching and profound impact of RAS signaling in associated processes. During vertebrate embryonal development, the FGF-RAS-ERK signaling axis is involved as early as germ layer induction and embryonal patterning. Current evidence suggests that RAS fundamentally controls the balance between stem cells and their differentiated progeny. RAS signaling needs to be downmodulated to sustain pluripotent stem cells. Inhibition of RAS activity is also required to preserve adult stem cell quiescence. At the other end of the differentiation spectrum, a different kind of RAS inactivation by the GTPase-activating protein (GAP) neurofibromin 1 (NF1) appears central to permit terminal differentiation, e.g., of muscle tissue. This latter process is disabled in muscle-borne cancer and likely also in other cancer types. In the RAS-associated developmental diseases, the RASopathies, cell differentiation appears to be broadly perturbed throughout development. We suggest that loss of RAS pathway activity mainly manifests in the stem/progenitor cell compartment, whereas inhibition of NF1 GAP-mediated RAS inactivation blocks terminal differentiation. Given that defects accumulate during development, it is plausible to assume that only progressive pathological phenotypes of RASopathies offer a realistic chance for treatment, notably by repurposing RAS-MAPK pathway oncology drugs. Thus, the impact of RAS on cell differentiation represents, in our view, the common mechanistic denominator of cancer and RASopathies. We conclude by giving a perspective on how improving our insight into the functioning of RAS during cell differentiation could lead to the development of misdifferentiation-correcting drugs.

Indexed as

Cell DifferentiationNeoplasmsras ProteinsAnimalsHumansSignal Transductionras Proteinscancerdevelopmental biologydifferentiationMAPKRASopathystem cell

Identifiers

PMID41248180
PMCPMC12751050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.